India's food regulator has questioned how a nutrition drink was sold to people on weight-loss therapy — and the wording at the centre of it involves muscles, protein and a class of medicines now prescribed at scale.
The Food Safety and Standards Authority of India (FSSAI) pulled up Dr Reddy's and Nestlé Health Science over Celevida's advertising, which presented the product as offering high-protein support for preserving lean muscle during GLP-1/GIP therapies, commonly used in weight-loss treatment.
Disclosure: This report is built on the FSSAI statement as described in the source material. Independent verification of the full order text and company responses was not available at the time of writing.
What the Regulator Says Was Advertised
According to the source material, the objection centres on a specific promise: that Celevida provides high-protein support to help preserve lean muscle in people undergoing GLP-1/GIP therapy.
That is not a general wellness claim. It is a claim tied to a prescription treatment pathway — which is precisely the kind of positioning food regulators tend to examine closely.
Why a Muscle-Loss Claim Sits at the Centre of This Case
Rapid weight loss affects lean muscle as well as fat, a point that clinicians and researchers have discussed for years. That concern has created real consumer demand for high-protein nutrition products.
For a brand, that demand is an opportunity. For a regulator, it is a claim that must be substantiated — because a buyer managing a medical condition may treat marketing language as clinical guidance.
Background: How India Regulates Food and Health Claims
FSSAI operates under the Food Safety and Standards Act and oversees labelling, health claims and advertising for food and nutraceutical products in India.
Companies are generally expected to ensure that claims made in advertising are accurate, substantiated and not likely to mislead consumers. What remains unclear in this case is which specific provision the regulator has invoked.
Who Actually Buys Celevida — And Why the Wording Matters
The people most likely to read that advertising are not casual shoppers. They are patients on or considering GLP-1/GIP therapy, often paying out of pocket, often anxious about losing muscle along with weight.
For them, the difference between "supports nutrition" and "preserves lean muscle during therapy" is not semantics. It is the difference between a supplement and something that sounds like part of treatment.
What FSSAI Has Said — And Where the Companies Stand
The regulator's position, as reflected in the source material, is that the product was advertised with a therapy-linked claim.
No public statement from Dr Reddy's or Nestlé Health Science was available in the material reviewed. Their position on the claim, and on whether it has been withdrawn or amended, is not established here.
Reading the Signal: Why Regulators Are Watching GLP-1-Adjacent Marketing
The action fits a wider pattern. As weight-loss medicines moved from specialist clinics into mainstream prescriptions, a parallel market grew around them — protein powders, meal replacements, fibre blends, "therapy support" drinks.
Regulators in several markets have begun asking whether that marketing borrows the authority of a prescription drug without carrying its evidence burden. This case reads as part of that scrutiny in India.
Confirmed Facts vs What Remains Unclear
Confirmed: FSSAI pulled up Dr Reddy's and Nestlé Health Science over Celevida claims, and the specific claim involved high-protein support for preserving lean muscle during GLP-1/GIP therapies.
Unclear: the legal instrument used, the date of the communication, whether any penalty or corrective advertising has been directed, whether the advertisement has been pulled, and how the companies have responded. Any reading beyond this is speculation and should be treated as such.
Why Dr Reddy's and Nestlé Health Science Are Big Names in Clinical Nutrition
Dr Reddy's is one of India's largest pharmaceutical companies, with deep distribution reach across pharmacies and hospitals — a channel that gives its nutrition brands direct access to patients, not just retail shelves.
Nestlé Health Science is the medical nutrition and science arm of Nestlé, with global expertise in clinical and therapeutic nutrition. A partnership of pharma distribution and nutrition-science credibility is a strong combination in this category — and it is also why a regulator's objection carries weight. The bigger the platform, the wider the claim travels.
The Risks on Both Sides of This Claim
For the companies, the immediate risk is reputational and procedural: corrective advertising, revised packaging or labelling language, and a slower path to market for therapy-linked positioning.
For consumers, the risk is subtler — treating a food product's advertising as a substitute for medical advice from the doctor who prescribed their therapy.
There is also a fair counterpoint: high-protein nutrition genuinely has a legitimate role in clinical care, and not every therapy-adjacent claim is misleading. The dispute here is about substantiation and wording, not about whether protein matters.
A Global Pattern: The Weight-Loss Boom Meets Nutrition Marketing
Wherever GLP-1 drugs have scaled, a nutrition industry has formed around them. That has pushed regulators to draw a sharper line between describing a food's nutritional content and implying a therapeutic outcome.
India's action is significant less for its size than for its timing — it signals that the line is being enforced here, early.
If You Use Celevida or GLP-1 Therapy, Here's What to Do
Do not stop or change a prescribed therapy based on a regulatory news item or a product advertisement. Speak to your treating doctor or a registered dietitian about protein intake and muscle preservation.
Read the label rather than the campaign. Check the nutrition panel, the protein content per serving, and whether the pack carries any claim a doctor has actually endorsed for your condition.
What Happens Next in the FSSAI Process
Typically, such matters proceed through company response, possible justification or modification of the claim, and regulatory follow-up if the response is found inadequate.
None of those steps can be confirmed at this stage. Watch for an official FSSAI statement, a company disclosure, or a change in how Celevida is advertised — those will be the first reliable signals.
Our Take
The story is not really about one drink. It is about what happens when a blockbuster class of medicines creates a consumer market overnight and marketing rushes in ahead of regulation.
FSSAI's intervention is a reminder that in food and nutrition, the burden of proof sits with the claim — not with the buyer. For a company selling into a therapy-driven market, the safest marketing is the kind a doctor would not object to.
Frequently Asked Questions
What did FSSAI object to in Celevida's advertising?
According to the source material, FSSAI pulled up Dr Reddy's and Nestlé Health Science over advertising that described Celevida as providing high-protein support for preserving lean muscle during GLP-1/GIP therapies.
What are GLP-1/GIP therapies?
They are a class of prescription medicines used to treat type 2 diabetes and, in many cases, for weight management. They work on gut and brain hormone pathways that influence appetite and blood sugar. They are commonly referred to as weight-loss injections.
Has Celevida been banned or recalled?
There is no indication in the available material that the product has been banned or recalled. The action concerns advertising claims, not a reported safety failure.
Should I stop using Celevida if I am on weight-loss therapy?
No — that decision belongs to your treating doctor. Use the label, not the advertisement, as your information source, and ask your doctor whether your protein intake is adequate for your therapy.
